Calidi Biotherapeutics Inc. (CLDI) Stock Analysis

Calidi Biotherapeutics Inc. (CLDI) is a publicly traded company in the HEALTHCARE sector. It trades at $0.18, carries a market capitalization of $3.54M. This page summarizes the public market data, fundamentals, and frequently asked questions for CLDI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $0.18
• Market Cap: $3.54M
• EPS: $-4.17
• 52-Week High: $13.20
• 52-Week Low: $0.16

Market Sentiment

Calidi Biotherapeutics Inc. currently has a Neutral sentiment score of 0.08.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics, Inc. (CLDI), based in San Diego, California, is a pioneering clinical-stage biotechnology company dedicated to advancing innovative immunotherapies for cancer treatment. Leveraging its proprietary platform of genetically modified oncolytic viruses, Calidi targets cancer cells with precision while simultaneously boosting the body’s immune response against tumors. With a robust pipeline of promising clinical trials and a firm commitment to addressing critical unmet medic...

GNG Research Analysis

GNG Research scores Calidi Biotherapeutics Inc. (CLDI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CLDI.

Frequently Asked Questions

Does CLDI pay dividends?

Calidi Biotherapeutics Inc. (CLDI) does not currently pay a regular dividend.

What is CLDI's market cap?

Calidi Biotherapeutics Inc. (CLDI) has a market capitalization of $3.54M with a current stock price of $0.18.